Verge Genomics Stock
Drug Discovery
Sign up today and learn more about Verge Genomics Stock
Invest in or value your shares in one or many pre-IPO companies through an EquityZen investment vehicle.
About Verge Genomics Stock
Verge Genomics transforms drug discovery with artificial intelligence. Verge was founded by a unique combination of the field's top machine learning experts and seasoned neuroscience drug developers. Together, they share the vision that exponential advances in computational genomics combined with new insights into neuroscience has created a breakthrough opportunity to discover drugs that dramatically improve the lives of patients suffering from neurodegenerative disease.
Investors
Draper Associates
Thumbtack, Webflow, Standard Cognition, Tempo Automation, Goldbelly, Aerospike, Samba TV, Indiegogo, Verge Genomics, CryptoMove
WuXi AppTec
LifeForce Capital
Cityblock Health, HeartFlow, One Medical, Clover Health, Grand Rounds Health, Vineti, Verge Genomics
ALS Investment Fund
Threshold
Zymergen, BetterUp, Talkdesk, Remitly, Divvy Homes, Prosper Marketplace, CircleCI, Viz, d.light design, Mythic
Funding History
| June 2018 | $370K |
|---|---|
| June 2018 | $150K |
| June 2018 | $100K |
| June 2018 | $3.4M |
| June 2018 | $4.5M |
| June 2018 | $28.2M |
Management
Co-Founder & Chief Executive Officer
Alice Zhang
Chief Business Officer
Jane Rhodes
Press
fiercebiotech - Apr, 6 2024
Ferrer signs $122M biobucks deal for ex-US license to Verge's phase 1 ALS therapyglobenewswire - Apr, 6 2024
Verge Genomics Announces Initiation of Proof-of-Concept Study for the Treatment of Amyotrophic Lateral Sclerosis ...bizjournals - Apr, 6 2024
Peninsula drug developer Verge Genomics strikes potential $122 million ALS drug deal with Ferrer - San Francisco ...globenewswire - Apr, 6 2024
Verge Genomics and Ferrer Announce Agreement to Co-Develop Clinical-Stage ALS Therapy VRG50635thepharmaletter - Mar, 25 2024
Ferrer pays for rights to Verge Genomics’ ALS candidateEquityZen Recognized As:
